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SEROLOGICAL  DISTINCTION  OF 
HEAVY  CHAIN  VARIABLE  REGIONS  (VH SUBGROUPS) 
OF MOUSE  IMMUNOGLOBULINS 
I. Common  VH Determinants on the Heavy Chains of  Mouse Myeloma 
Proteins Having Different Binding Sites* 
BY M. J.  BOSMA,  C.  DE  WITT, S. J.  HAUSMAN,~  R.  MARKS,  AND M.  POTTER 
(From The Institute for Cancer Research,  Fox Chase Cancer Center, Philadelphia, Pennsylvania 
19111, and The National Cancer Institute, Bethesda,  Maryland 20014) 
Extensive sequence homologies in the variable  (V)  I  regions  of  Ig heavy (H) 
and  light  (L)  chains allow  for  the  division  of  V regions  into  subgroups (reviewed 
in  references  1-4).  Members of  the  same subgroup  have  primary  structures  more 
related  to each other than to those of  any other  subgroup. Only the relatively 
invariant residues are used to classify  subgroups; hypervariable residues are 
ignored. 
Evidence for the serological  detection  of  V subgroups was first  reported for 
human kappa chains by Solomon and McLaughlin (5).  Serologic  typing of K- 
chains into  three distinct  groups correlated  with their  division  into  three basic 
sequences, KI, KII,  and KIII  (6, 7). Evidence for subgroup-specific  antigens on 
human lambda (k)  chains  was described  shortly  thereafter  by  Tischendorf  et  al. 
(8).  Recently,  Fcrre et  al. (9)  reported  antisera  that  distinguish  the three  major 
H chain V region (VH)  subgroups in humans. Especially  relevant  to the latter 
report  is our recent evidence for the serological  detection  of VH subgroups in 
mice (10).  This is  detailed  in the present report. 
Materials and Methods 
Mouse Plasmacytomas.  Most of  the myeloma proteins  tested  in this  study derive from NIH 
BALB/c plasmacytomas. Three tumors came from The Salk Institute,  La Jolla,  Calif.;  J539 was 
supplied  by Dr. M. Cohn and serum from Y5476-  and W3082-bearing mice  was given  to  us  by Dr. 
M. Weigert. Myeloma proteins  from  plasmacytomas  not  induced  in  BALB/c mice  included:  C × BH 
PC-1 (from a mouse of  Bailey's  C x BH recombinant  inbred line)  (11);  CBPC 4 and PC 3 [from Ig- 
* Supported by U. S. Public Health Service grants AI-13323, CA-04946, CA-06927, and RR-05539 
from the National Institutes of Health,  and by an appropriation from  the  Commonwealth of 
Pennsylvania. 
Present address:  Laboratory of Cellular and Comparative Physiology,  Gerontology Research 
Center, Baltimore City Hospitals, Baltimore, Md. 21224. 
Abbreviations used  in this paper:  BSA,  bovine serum albumin; CHI, first constant region 
domain of H chain; CHO,  carbohydrate; 1,6-Gal,  ~-l,6-D-galactopyranosyl residues; GNAc, N- 
acetyl-glucosamine; 2,6-Lev,  /3-2,6-fructosan;  LR,  linear regression;  ManNAe, N-acetyl-man- 
nosamine; PBS,  phosphate-buffered saline; V, variable region; Vx, variable region of H chain; 
VL, variable region of L chain. 
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congenic BALB/c mice that carry the allotype genes of C57BL/Ka (C.B mice)]; and 3660 (induced 
in a  NZB mouse by Dr. M. Weigert, Institute for Cancer Research, Philadelphia,  Pa.). 
BALB/c myeloma proteins of particular interest to this study are those (ABE 48,  Y5476,  and 
U10) with specificity for levan, a  ~-2,6-fructosan  (2,6-Lev) (12,  13); and those (T191,  S10,  JPC-1, 
X44, X24, J539, and T601) with specificity for ~-l,6-D-galactopyranosyl residues (1,6-Gal) (14, 15); 
two proteins (173 and PC 3) with unknown binding specificity; one protein (M406) with specificity 
for N-acetyl-mannosamine  (ManNAc)  (16);  and one protein "(Sl17)  that binds N-acetyl-glucosa- 
mine (GNAc) (17). Serum from SliT-bearing mice was given to us by Dr. R. Riblet, Institute for 
Cancer Research, Philadelphia,  Pa. 
Purification  of Myeloma  Proteins.  Chromatographically pure  IgG2a proteins  (173,  U10,  and 
LPC-1) were obtained by precipitating the serum Ig of tumor-bearing mice with 50%  (NH4)2SO4 
followed by passage of the Ig preparation over a DEAR-cellulose column (at 0.02  M PO4, pH 7.4). 
IgGa from the J606 tumor was purified by selective precipitation according to the method of Grey et 
al. (18). 
The IgA proteins, ABE 48, and C  ×  BH PC-1 (gifts of Dr. J. Slack, National Cancer Institute, 
Bethesda, Md.) and X44 and T601  (gifts from Dr. N. Glaudemans, Lung Cancer Branch, National 
Institute of Arthritis, Metabolism and Digestive Diseases, Bethesda, Md.), Were specifically puri- 
fied by elution from 2,6-Lev derivatized to bovine serum  albumin-Sepharose  (BSA-Sepharose) 
and from 1,6-Gal-BSA-Sepharose (19,  20). Samples of purified Sl17 were supplied by both Dr. K. 
Eichmann  (Institute  for  Immunology  and  Genetics,  German  Cancer  Research  Center,  West 
Germany), and Dr. N. Klinman, Department of Pathology, University of Pennsylvania School of 
Medicine, Philadelphia,  Pa. These were prepared by affinity chromatography on p-aminophenyl- 
GNAc coupled to Sepharose (21). 
Preparation  of Myeloma H and L Chains.  Reduction and alkylation of 173, U10, LPC-1, and 
J606 and the subsequent separation of the H and L chains was done by the method of Bridges and 
Little (22), the only difference being that the chains were separated over columns of Sephadex G- 
150 instead of G-100.  Examples of gel filtration profiles of H and L chains from 173 and U10 are 
shown in Fig.  1.  The ratio of the total absorbency of the H/L chain peaks was close to 2.0 and 
therefore the reduction of H  and L chains was virtually complete. 
Separated H and 1 chains were dialyzed against 100-fold and then 10-fold  volumes of distilled 
water. This removed most of the urea and propionic acid and elevated the pH of these preparations 
to about 5. In this condition, the H and L chains remained soluble except the J606 H chain which 
precipitated after several days in the cold (4°C). All H and L chain preparations were diluted to the 
low microgram range in phosphate-buffered saline, pH 7.4 (PBS) immediately before their use as 
competitors in a radioimmune assay. Lyophilized H and L chains of X44 were supplied by Dr. S. 
Rudikoff, Laboratory of Cell Biology, National Cancer Institute,  Bethesda,  Md. 
Rabbit Anti-173 Fab Serum.  IgG~a Fab  fragments  of 173  (173 Fab)  were  obtained  by  the 
method of Fahey and Askonas (23). A total of ~ 10 mg of 173 Fab was injected intramuscularly into 
a New Zealand rabbit over a period of 9 mo; each injection of 173 Fab (0.5-1.0 mg) was given in 
complete Freund's adjuvant.  After the fifth injection, the rabbit  was bled periodically and the 
antiserum stored at  -70°C. 
The antiserum was made specific for 173 Fab determinants by absorption with Sepharose beads 
(Pharmacia Fine Chemicals, Inc., Piscataway,  N. J.) containing IgG~a from the LPC-plasmacy- 
toma (LPC-1 Sepharose) [see method of Axen et al. (24)]. After repeated absorptions with LPC-1 
Sepharose,  anti-173  Fab failed to react with a  panel of myeloma proteins representative of the 
major Ig classes,  i.e.  IgM (MOPC  104E),  IgA (MOPC  167), IgGl (MOPC  31c),  IgG2a  (Adj PCb, 
HOPC-1, and LPC-1), and IgG2b (MOPC 195). The restricted specificity of this absorbed antiserum 
for determinants on the 173 Ig is referred to as anti-173.  As we show later, the IgG2a of another 
plasmacytoma (U10) shares some determinants with 173. We refer to this cross-reacting specificity 
as U10-173. 
Radioimmune  Assay  for 173  and  U10-173.  173-reactive  polystyrene  tubes  were  made  as 
follows (25): 12 × 75 mm culture tubes (no. 2054; Falcon Plastics, Div. ofBioQuest, Oxnard, Calif.) 
were coated sequentially with 1 ml of a protein solution containing 5 ftg of 173 and 95 ~tg of BSA, 
with 6 ml of 0.5%  BSA in PBS and with 1 ml of anti-173 serum (1/200 dilution). To prevent the 
dissociation of the antibody from the tube surface in subsequent steps, the antigen and antibody 
were covalently cross-linked by means of 2.5  ×  10  -~ M glutaraldehyde.  U10-173-reactive tubes 
were made in the same manner except U10 was substituted for 173. Competition reactions between BOSMA,  DE  WITT, 
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Fro.  1.  Gel filtration profiles of separated H and L chains from two IgGsa-preducing mouse 
plasmacytomas, MOPC 173 (A) and UPC 10 (×). The reduced and alkylated proteins were 
applied to separate Sephadex G-150 columns (2.5 x  80 cm) that were previously equilibrated 
with 1 M propionic acid in 4.5 M urea. Eluent fractions having an absorbency greater than 
1.2 from the descending limb ofthe first peak (H chains) were pooled; those fractions having 
an absorbency greater than 0.5 on the descending limb of the second peak (L chains) were 
pooled. The ratio of the total absorbency of the H/L chain peaks was close to 2.0. 
50 ~g of labeled antigen, t~sI-173 or lzsI-U10, and varying concentrations of unlabeled antigen were 
then carried 5ut in these 173- or U10-173-reactive tubes, The reference antigen in the competition 
reactions was always the same as that used initially to coat the tube surface. As competitors, H 
and L chains were either added separately or together in different combinations to 173- or U10-173- 
reactive tubes. For all H and L chain mixtures, the H/L absorbency ratio was held constant at 2/1. 
Protein concentrations of Ig, H, or L chain solutions were determined from their absorbence (280 
nm) using an extinction coefficient (E 1% cm) of 15. Ig preparations were radioiodinated with '~I 
by the method of Hunter and Greenwood (26) to give a specific activity ranging from 0.4 to 1.0 x  106 
cpm//~g protein. 
lmmunoabsorption of Myeloma Proteins.  2,6-Lev-BSA-Sepharose and 1,6-Gal-BSA-Sepharose 
were given to us by Dr. N. Glaudemans. These immunoabsorbents, together with LPC-1 Sepha- 
rose,  were used batchwise to absorb solutions of ~2sI-173, '~I-U10,  1~I-X44,  and lUI-T601.  Each 
solution was absorbed three to four times with a 5% volume of Sepharese beads and then counted 
in an Autogamma Spectrometer (Packard Instrument Co., Inc., Chicago, Ill.) to determine how 
much label was specifically removed. 
The maximum quantity of label protein that could be removed by U10-173-reactive tubes was 
determined as previously described (25).  Limiting quantities of the above labeled proteins were 
added to U10-173-reactive tubes. In this range of antigen addition, the proportion of label bound is 
independent of the amount added and it corresponds to the fraction of U10-173 antigen in each of 
the labeled solutions (173,  U10, X44, and T601). 
Results 
Assay for U10-173 Determinants.  Rabbit  antiserum  specific  for the  IgG2a 
Fab  fragment  of 173  (anti-173)  was found to react with one of six other IgGsa 1044  VH 
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Fro.  2.  (a) Antigen competition in 173-reactive tubes between 50 ng of'~I-173 and known 
concentrations of unlabeled 173 (0) and U10 (A); and (b) antigen competition in U10-173- 
reactive tubes between 50 ng of '~I-U10 and known concentrations of unlabeled 173 (0) and 
U10 (A).  In this and subsequent figures,  cpm bound is plotted as percent of control  (no 
unlabeled competitor added); in the 173- and U10-173-reactive tubes, approximately 25-50 x 
10  ~ cpm were  bound to  the control tubes.  Each  point represents the mean of triplicate 
determinations. 
myeloma proteins of BALB/c mice.  This cross-reaction occurred with U10,  a 
myeloma protein that specifically binds 2,6-Lev; the specificity of 173 is not yet 
known.  The distinction between 173  determinants shared  (U10-173) and not 
shared (173) is made in Fig. 2a. As shown, the addition of 103 ng of 173 into 173- 
reactive tubes reduced the uptake of 1~51-173 to -10% of the control value (no 
unlabeled competitor added), whereas 10  ~ ng of U10 was not able to reduce the 
uptake of '~51-173 to less than 80% of control. Therefore, U10 could compete for 
only about 20% of the anti-173 antibodies. To measure these U10-173 determi- 
nants exclusively, we coated polystyrene tubes with U10 followed by anti-173 
antibodies and carried out antigen competition reactions with a fixed weight of 
125I-U10 instead of '251-173. The results are seen in Fig. 2b. Here, U10 and 173 
were indistinguishable and 103  ng of either reduced the uptake of '~I-U10 to 
<10%  of the  control  value.  Substituting  '2sI-173 for  '25I-U10 gave  the  same 
results as shown in Fig. 2 b and therefore U10-173-reactive tubes must recognize 
the same determinants on both 173 and U10. 
Evidence for U10-173 Determinants on 13 of 58 IgA Myeloma Proteins.  The 
possibility that other BALB/c myeloma proteins might carry U10-173 determi- 
nants (U10-173 ÷) was evaluated as follows: 10  -~ dilutions of  each of 102 sera from 
mice bearing different Ig-producing tumors,  together with 50  ng of 125I-U10, 
were added to U10-173-reactive tubes. 10  -~ dilutions of serum from normal mice 
and from mice bearing the UPC-10 tumor served as negative (U10-173-)  and 
positive (U10-173 ÷) controls, respectively. Table I shows that sera from 13 of 58 BOSMA,  DE  WITT,  HAUSMAN,  MARKS,  AND  POTTER 
TABL~  I 
Detection of U10-173 in 13 of 102 Different BALB/c Myeloma 
Sera* 
Ig class of myeloma  No. tested  No. positive 
IgM  3  0 
IgA  58  13 
IgG~  10  0 
IgG2a  5  0 
IgGsb  7  0 
Miscellaneous  19  0 
*  10  -5 dilutions of each serum sample, together with 50 ng of l*sI-U10, 
were  added to  U10-173-reactive tubes.  Sera from normal  mice  and 
from mice bearing the UPC-10 tumor served as negative and positive 
controls, respectively. 
1045 
TABLE  II 
Comparison of Different  [110-173  +  Myeloma Sera; Evidence for Similar U10-173 
Determinants  on Myeloma Proteins Having Different Ligand-Binding Specificities 
U10~173 + myeloma  Ligand specific- 
Group  sera  ity 
Comparison of competitive curves; serum dilu- 
tion needed to reduce l*sI-U10 uptake by 50%* 
LR  Slope  50% values 
A  173  Unknown  -0.994  -2.17  1.6  ×  10  -e 
PC 3  -0.993  -2.25  2.3  ×  10  -e 
B  ABE 48  2,6-Lev  -0.941  -1.93  - 
U10  -0.993  -2.32  1.0  x  10  -6 
Y5476  -0.995  -2.33  0.9  ×  10  -e 
C  T191  1,6-Oal  -0.999  -2.34  7.9  x  10 -e 
S10  -0.998  -2.36  9.9  ×  10  -e 
JPC-1  -0.997  -2.32  6.0  ×  10  -e 
X44  -0.982  -2.05  19  x  10  -e 
X24  -0.830  -0.936  - 
D  Sl17  GNAc  -0.994  -2.16  1.4  ×  10  -e 
E  M406  ManNAc  -0.991  -2.61  26  ×  10 -e 
F  MOEV 48  Unknown  -0.964  -2.40  71  x  10 -e 
G  BALB/c serum  -0.994  -2.03  47  x  10  -5 
* Relative to control (no unlabeled competitor added), the logit of the percent IssI-U10 bound [ln (% 
of control/100-% of control)] was plotted as a function of the dilution of myeloma serum added. 
This yielded a family of lines for which the coefficients of LR, the slopes, and the 50% values are 
shown. The two exceptions, ABE 48 and X24, are discussed in the text. Three U10-173  + myeloma 
sera not listed in group C are T601, J539, and CBPC-4. 
mice  bearing  different  IgA-producing  tumors  were  U10-173 +.  The  remaining 
sera  were  U10-173-. 
Radioimmune Analysis of [I10.173 + Myeloma Sera.  10 of the  13 IgA  mye- 
loma  proteins  classified  as  U10-173 +  in  Table  I  are  listed  in  Table  II  (the 
remaining  three  are  indicated  in the  footnote  of Table  II).  Included  in this  list 1046  V H  SUBGROUP  ANTIGENS  ON  MOUSE  IMMUNOGLOBULINS 
are the two IgG2a proteins of Fig. 2 (173 and U10) plus an additional U10-173  ÷ 
protein (PC 3) from a plasmacytoma that originated in a C.B-17 mouse (27). The 
grouping of these proteins is according to their ligand-binding specificities. 
In Table II, we compare the ability of different myeloma sera to compete with 
12sI-U10 for U10-173-reactive antibody. Serial dilutions of each myeloma serum, 
together with a fixed quantity of 1~5I-U10 (50 ng), were added to U10-173-reactive 
tubes. Differences in competitive ability between myeloma sera are expressed as 
the dilution of serum required to reduce the uptake of 1~5I-U10 by 50%. Except for 
ABE 48 and X24, all of the myeloma sera of groups A-D reduced the uptake of 
125I-U10 to <10% of control (no unlabeled competitor added).  Logit transforma- 
tion of these data, i.e., plotting the logit of the percent I~I-U10 bound relative to 
control [ln (% of control/100% ofcontrol)] as a function of the dilution ofmyeloma 
serum added, yielded lines of comparable slope having linear regression  (LR) 
coefficients close to 1. The last two myeloma sera of groups E  and F  gave logit 
lines similar to those of groups A-D,  but due to the low concentration or low 
affinity of U10-173 + protein in these sera, we could not practically reduce the ~25I- 
U10 label below 35% of control. To do so would have required serum dilutions in 
which background quantities of U10-173 in BALB/c serum are detectable (see 
group  G).  Contrasting  the above,  myeloma sera of ABE 48 and  X24 acted as 
incomplete competitors and were unable to reduce the uptake of 125I-U10 below 
50% of control.  Moreover, logit transformation  of these data gave lines having 
lower LR coefficients and more shallow slopes than any of the other myeloma 
sera. The same results were obtained with purified ABE 48 and X24 (not shown). 
Two conclusions can be made from the results of Table II. First, that ABE 48 
and X24 apparently lack some U10-173 determinants.  Second, that the remain- 
ing myeloma sera contain similar U10-173 determinants;  how similar depends 
on the extent to which differences in reactivity (50% values) reflect differences in 
U10-173 concentration and/or affinity of antibody for each U10-173 ÷ protein. 
Radioimmune  Analysis  of Purified  U10-173 + Myeloma Proteins.  Specific 
immunoabsorption of purified myeloma proteins representative of groups A-D 
in  Table  II was  carried  out to  answer the  following:  do these  proteins  have 
noncross-reacting ligand-binding specificities and do the same molecules carry 
both the ligand-binding  sites and the U10-173 determinants? 
In  Table  III,  a  comparison  between two  immunoabsorbents,  2,6-Lev-BSA- 
Sepharose  and  1,6-Gal-BSA-Sepharose,  shows  that  125I-U10 was  specifically 
absorbed by 2,6-Lev-BSA-Sepharose (group B). Conversely, ~25I-X44 was specifi- 
cally removed by 1,6-Gal-BSA-Sepharose (group C). The high background in the 
controls of group C (2,6-Lev-BSA-Sepharose and LPC-1 Sepharose) was presum- 
ably due to the presence of the galactosyl residues in Sepharose (see Pharmacia 
handbook). None of the above immunoabsorbents were able to remove 1251-173. 
Thus,  it was clear that the 2,6-Lev- and  1,6-Gal-binding  specificities are non- 
cross-reactive and that  173 recognizes neither of these two ligands.  The lower 
uptake  of 125I-X44 vs.  ~25i-T601 by  U10-173-reactive  tubes  probably  reflected 
radiolabeling damage of the ~25I-X44 preparation since it was several weeks older 
than that of~25I-T601. As most of the ~25I label in groups A-D of Table III was re- 
moved  by U10-173-reactive  tubes  and  by the  appropriate  ligand  immunoab- 
serbent as well (groups B and C), the answer to the above question is affirma- 
tive. BOSMA,  DE  WITT,  HAUSMAN,  MARKS,  AND  POTTER 
TABLE  III 
Immunoabsorption of ~251-Labeled U10-173  +  Myeloma Proteins 
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Percent  of  label  removed by immunoabsorbent 
Group  Labeled myeloma 
protein  U10-173-re-  2,6-Lev-BSA-  1,6-GaI-BSA-  LPC-1 Seph- 
active tubes  Sepharose  Sepharose  arose 
A  ~51-173  87  9  6  12 
B  ~2sI-U10  83  87  11  17 
C  125I-X44  72  32  70  45 
125I-T601  89  ND*  ND  ND 
* ND, not done. 
Ligand-Binding  Specificities  of U10-173 + Myeloma Proteins.  At least five 
different ligand-binding specificities are represented in Table II: unknown speci- 
ficities (groups A and F); 2,6-Lev (group B); 1,6-Gal (group C); GNAc (group D); 
and ManNAc (group E). It should be noted that all three of the known 2,6-Lev- 
binding myeloma proteins of BALB/c were U10-173  ÷, whereas two other mye- 
loma proteins  specific for  2,6-Lev,  CBPC-2  (from a  C.B-20  mouse),  and  3660 
(from an NZB mouse) were U10-173-. Further, all of the 2,1-Lev-binding myelo- 
mas (13) that were tested lacked U10-173 determinants  (ABE 4,  ABE 47, EPC 
109,  UPC 61, J606,  and W3082). Finally,  with respect to 1,6-Gal-binding  mye- 
loma proteins,  a perfect correlation seemed to hold as all of these proteins were 
U10-173  + including one that was induced in a  C.B-20 mouse (CBPC 4). 
Dependence  of 173 Determinants  on  the  Combination  of H  and L  Chains. 
Since  U10-173  seemed to  represent  nonbinding  site  determinants,  it  was  of 
interest  to  study what  role  H  and  L  chains  played  in  forming  the  U10-173 
structure. For this purpose, it was helpful to evaluate first the contribution of H 
and L chains to the antigenicity of the 173 structure. 
It is clear from Fig. 3 that a mixture of 173 H and L chains was as effective in 
competing for r'51-173 as was intact 173 Ig (see stippled curve), i.e., both competi- 
tive curves reached ~10% of the control value after the total addition of 1,000 ng 
of unlabeled competitor.  When the same weights of 173 H  and L  chains were 
added  separately  or  together  with  LPC-1  L  and  H  chains,  respectively,  the 
competition curves were shifted markedly to the right and assumed a  different 
shape than  that  of the  173H-173L curve.  The simplest interpretation  for this 
cooperation between 173H and 173L chains is that the structure of 173 determi- 
nants depends on the interaction of both subunits. Thus, H  and L chains must 
recombine in 173-reactive tubes after overnight incubation at 4°C. This is in fact 
expected  since  others  have  already  demonstrated  that  mildly  reduced  and 
alkylated  H  and  L  chains  will  recombine  noncovalently  under  conditions  of 
neutral pH (22,  28). 
Comparable  competitive curves to those of 173H-LPC-1L and  LPC-1H-173L 
resulted when L and H chains from J606 were substituted for LPC-1 (not shown). 
This did not happen,  however, when mixtures of H  and L chains between 173 
and U10 were added to 173-reactive tubes. As shown in Fig. 3, the combination 
of 173H and  U10L helped restore the  173 structure.  This  is evident from the 
shape of the 173H-U10L curve and from its position relative to that of 173H-LPC- 
1L. The reverse combin;tion of U10H-173L also partly restored the 173 structure 
(not shown).  This means that the H  and L chains of U10 and  173 must share 1048  V H  SUBGROUP  ANTIGENS  ON  MOUSE  IMMUNOGLOBULINS 
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FIG.  3.  Contribution of H and L chains to the structure of 173 determinants. 50 ng of 1251- 
173 was added into 173-reactive tubes along with increasing weights of unlabeled H and L 
chains, added separately or together as follows: 173H +  173L (A--A); 173H +  U10L (O--O); 
173H +  LPC-1L (x--x)  for which only the H chain concentration is plotted; 173H (V--V); 
and LPC-1H +  173L (@--O). The ratio of H/L in the subunit mixtures was held constant at 
1/1, i.e., the absorbency (280 nm) ratio of H/L was 2/1. The stippled line corresponds to the 
competitive curve obtained with intact 173 as unlabeled competitor (see Fig. 2).  Tabulated 
on the right-hand side of the figure is the nanograms of competitor needed to reduce the 
uptake of 12~I-173 by 50%. 
certain homologies in their primary structure. In support of this conclusion is 
the fact that available N-terminal VH and light chain V region (VL) sequences of 
173  (29, 30) and U10  (S.  Rudikoff, personal communication) are each, respec- 
tively, very similar to one another. 
From the total weight of  H and L chains needed to reduce the uptake of 1251-173 
to 50% of control, H and L chain recombination was about 60% efficient relative 
to intact 173  as  a  competitor (see stippled curve of Fig.  3).  This  may be  an 
underestimate as recombination of H and L chains appeared to be concentration 
dependent,  i.e.,  recombination was  more  complete  at  total  H  and  L  chain 
concentrations of 1,000 ng than at 200 ng. This criterion for recombination of H 
and L chains does not, of  course, distinguish between HL dimers (or aggregates) 
and four-chain molecules (H2L2). 
A  comparison of the quantities of H  or L  chain competitor needed for 50% 
reduction of 1251-173 uptake is tabulated in Fig. 3. For example, approximately 
200  x  102 ng of 173H had to be added to 173-reactive tubes in order to displace 
50% of the 173 label. This was true whether 173H was added alone or together 
with unrelated L chain (173H  +  LPC-1L). But in the presence of 173L, only 0.86 
x  102 ng of 173H was needed to displace 50% of  the labeled 173. The magnitude of 
this difference in reactivity can be interpreted to reflect less than 1% contamina- 
tion of  the 173H preparation with unreduced and unseparated HL, H2L, or H~L2. 
Likewise, the low reactivity of 173L-LPC-1H can be ascribed to contamination of 
the 173L preparation. An alternate interpretation is that 173H and 173L chains 
retain enough homology to the intact 173 so as still to bind to anti-173 but with a 
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FIG.  4.  Contribution of H and L chains to the structure of U10-173 determinants. 50 ng of 
~ssI-U10 was added into U10-173-reactive tubes along with increasing weights of unlabeled 
H and L chains, added separately or together as follows: U10H +  U10L (/x--A); X44H (1'1); 
173H (D--D); U10H (V--V); U10H +  J606L (x--x)  for which only the H chain concentra- 
tion is plotted; 173L (e--e);  and U10L (O--O).  The ratio of H/L in the subunit mixtures 
was held constant at 1/1, i.e., the absorbency (280 nm) ratio of H/L was 2/1. Tabulated on the 
right-hand side of the figure is the nanograms of competitor needed to reduce the uptake of 
1~5I-U10 by 50%. 
Nondependence  of U10-173  Determinants on  the  Combination of H  and L 
Chains.  Unlike 173 determinants which required that both H and L chains be 
in combination with  each  other,  the  U10-173 determinants showed  no  such 
requirement. This became evident when various H  and L  chains were added 
separately or together into U10-173-reactive tubes in the presence of  50 ng of 125I- 
U10  (see Fig. 4).  Consistent with the low activity of 173L in 173-reactive tubes 
(Fig. 3),  the ability of 173L or U10L to displace 125I-U10 was 38-70  times less 
efficient than the same weight of U10L mixed with U10H.  On the other hand, 
173H,  U10H,  and  also  X44H  were  only two  to  three times  less  efficient in 
displacing 125I-U10 than the same weight of U10H mixed with U10L. In the case 
of 173H, the competitive ability could not be attributed to HL contamination as 
the same 173H preparation was judged to be virtually pure according to the data 
of Fig. 3. Therefore, we conclude that U10-173 determinants are on the H chains 
of 173. Per  unit  weight of competitor added,  173H,  U10H,  and  X44H  gave 
comparable results: therefore, the H chains of all these proteins must share very 
similar, if not identical, U10-173 determinants. 
It is possible that the configuration of U10-173 determinants might be influ- 
enced by the U10L chain. As shown in Fig. 4, the same weight of U10H competed 
~three times more efficiently when added with U10L than with J606L or then 
when added by itself A reasonable interpretation of this is that antibodies to 
U10-173  have greater affinity for U10H when it is combined with U10L than 
with J606L. 
Discussion 
We  have  presented evidence for similar  H  chain  antigens  (U10-173) on  a 
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carbohydrate (CHO) ligauds (2,6-Lev, 1,6-Gal, GNAc, and ManNAc) and on a 
few myeloma proteins having unknown binding site specificities. What follows 
in two parts is the basis for concluding that U10-173 is an H chain antigen and the 
rationale that U10-173 is a  Vn framework antigen shared by a small number of 
related Vn subgroups. 
Evidence that U10-173 Determinants are on H  Chains Alone.  The presence 
of U10-173 determinants on H chains was ascertained by comparing the ability 
of isolated H  and L chains to compete with labeled antigen in 173-reactive or 
U10-173-reactive tubes. In such tubes, unlabeled H and L chains could be mixed 
and  recombined  after  overnight  incubation  at  4°C. Alternatively, H  and  L 
chains could be added separately. Thus, the ability of H and L chains to reduce 
the  uptake of labeled antigen related to whether the  antigenic structure  in 
question required only one subunit or the interaction of both subunits. In this 
way, we found that the addition of increasing weights of 173H and 173L chain 
mixtures into 173-reactive tubes competed as effectively for 1251-173 as did the 
intact 173 molecule. On the other hand, 173H and 173L chains acted as incom- 
plete competitors when added separately into 173-reactive tubes in the same 
concentration  range  as  in  the  mixtures.  This  result  was  not  changed  by 
interacting 173H chain with unrelated L chains from tumors LPC-1 and J606. 
However, the antigenic structure of 173  could be partly restored if reciprocal 
combinations of H  and L chains of U10 and 173  were added into 173-reactive 
tubes. Therefore, it was clear that the structural determinants for 173 required 
the combination of a specific H and L chain and that both the H and L chains of 
U10 and 173 shared certain homologies in their primary structure. 
The importance of the 173 characterization was that it enabled us to interpret 
the competitive curves in the U10-173 system. Here,  H  chain preparations of 
U10 or 173 gave competitive curves that were displaced by only a factor of 2-3 to 
the right of the U10H-U10L recombinant curve, whereas the competitive curves 
generated by L chains of U10 or 173 were shifted to the right of the U10H-U10L 
curve by a  factor of 15-25.  This result could not be attributed to 25% or more 
contamination of the  H  chain preparations  with HL aggregates because the 
173H chain preparation behaved in 173-reactive tubes as if it were 99% pure, 
whereas  173L chains were estimated to have the same order of reactivity or 
impurity (1-3%)  when assayed in either system. Therefore, we concluded that 
U10-173 determinants are on the H chains alone. 
Rationale that U10-173  is a  VHFramework Antigen.  That U10-173 determi- 
nants  are  on  the  VH  was  suggested from the  results  of screening over  100 
myeloma proteins in U10-173-reactive tubes. First, U10-173 determinants were 
found on 13 of 58 IgA proteins and on 3 of 8 IgG~a proteins. It seems unlikely that 
these determinants would correspond to the first constant region domain (CHI) 
of some IgA and IgG2a H chains as then we would have to postulate subclasses of 
IgA and IgG2~ having similar CHI regions. A second indication for VH determi- 
nants  was the  restricted association of U10-173 with proteins  having one of 
several  anti-CHO  specificities.  U10-173 + proteins  included all  of the  known 
BALB/c myeloma proteins specific for 2,6-Lev (ABE 48, U10, and Y5476) and all 
those specific for 1,6-Gal (T191, S10, JPC-1, X44, X24, J539, T601, and CBPC4), 
plus Sl17 and M406 which are specific for GNAc and ManNAc residues, respec- 
tively. A fourth and different ligand-binding specificity was inferred for 173 and BOSMA,  DE  WITT,  HAUSMAN,  MARKS,  AND  POTTER  1051 
PC 3 as these two proteins give indistinguishable  isoelectric-focusing spectra 
(unpublished results) and do not bind 2,6-Lev or 1,6-Gal. 
The demonstration of very similar,  if not identical,  U10-173 determinants on 
the  H  chains  of 173,  U10,  and  X44,  each  representing  a  different  group  of 
myeloma proteins  having  noncross-roacting  ligand-binding  specificities,  indi- 
cated that  we were not dealing  with hypervariable  amino  acid residues that 
form the binding site. Thus, we presume that U10-173 determinants correspond 
to framework residues outside the hypervariable regions, and that considerable 
portions of the VH framework of proteins in groups A-E of Table II are identical 
or nearly so. Available structural  data support this view. The N-terminal  VH 
sequences of U10-173  + proteins SI0,  T191,  X44 (14),  $117 and  Y5476 (30),  and 
U10 (S.  Rudikoff, personal  communication)  are identical  through  the first 27 
residues; those of JPC-I (14),  173 (24) and M406 (16) differ by no more than two 
replacements through the first 20-27 residues.  Further,  a comparison between 
the completed V s sequence of 173 (29) and the nearly completed VH sequence of 
J539  (31)  shows only four framework  residues  that  are  different.  It  is  to  be 
expected that purified VH peptides of 173 or J539 (or of UI0) would be useful in 
attempting to localize U10-173 determinants.  Such peptides could be tested for 
their ability to inhibit the uptake of 1251-UI0 in U10-173-reactive tubes. 
Two different interpretations  can be given to the UI0-173 data.  The first is 
that U10-173  + proteins correspond to at least five different VH germ-line genes. 
Here,  the  rationale  is  that  one  or more  replacements  in  the  VH framework 
defines a distinct VH germ-line gene. Somatic theories of antibody diversity that 
presume mutation occurs predominantly in the hypervariable region or is only 
detectable in these regions due to antigenic selection (32), as well as germ-line 
theories  of antibody diversity  (see references 4 and  30),  would argue for this 
interpretation.  We  know  from  other  data  (I0)  that  UI0-173  represents  only 
about 1% of the total Ig fraction; therefore, five or more UI0-173 VH genes may 
account for the expression of 1% of all V~ genes and accordingly there could be as 
many as 500 VH genes in the germline.  An alternative  idea to the above is to 
consider the VH frameworks of UI0-173  + proteins so similar as to represent the 
product of one VH germ-line  gene.  If somatic mutations of VH genes were not 
restricted  to  hypervariable  regions  and  were  to  occur  with  unusually  high 
frequency,  one  could attribute  minor  differences between VH  frameworks  to 
mutations  that  do not  seriously change  the  configuration  of VHVL domains. 
Accordingly,  five or  more  different  anti-CHO  specificities  might  be  realized 
when VH products of one UI0-173 germ-line gene are paired with appropriate VL 
gene products. 
Summary 
16 of more than 100 mouse myeloma proteins, including 3 proteins of the IgG~a 
class and 13 of the IgA class, were shown to have a similar heavy chain variable 
region (VH) antigen(s)  (U10-173). The proteins bearing these antigenic determi- 
nants  (U10-173  +  proteins)  represented  at  least  five  different  ligand-binding 
specificities. These findings, taken together with available sequence data for VH 
regions  of U10-173  + proteins,  have  led us to conclude that  U10-173 defines a 
small  number of related  V~ subgroups.  The ability to detect VH subgroups in 1052  v H  SUBGROUP  ANTIGENS  ON  MOUSE  IMMUNOGLOBULINS 
mice by serological means, as has been done in humans also, promises new and 
useful kinds of VH markers for immunologic study. 
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to N. Glaudemans for giving us 2,6-Lev-BSA-Sepharose and 1,6-Gal.BSA-Sepharose beads. 
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